AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients

Journal of Immunotherapy

Volumn 30, Issue 4, 2007, Pages 425-437

  Evdokimova, Viktoria N ^a   Liu, Yang ^a,e   Potter, Douglas M ^b,c   Butterfield, Lisa H ^a,d  

^a Division of Hematology/Oncology   (United States)

^b GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Biostatistics Facility   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antigen presentation; Dendritic cells; T cells; Vaccination

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; CYTOKINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LYMPHOCYTE FUNCTION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; TH1 CELL; VACCINATION;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; LYMPHOCYTE ACTIVATION; MALE; PEPTIDES; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 34247638420     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31802fd8e2     Document Type: Article

References (71)

1. Levin B, Amos C. Therapy of unresectable hepatocellular carcinoma [editorial; comment] [published erratum appears in N Engl J Med.1995 Sep 7;333(10):675]. N Engl J Med. 1995;332:1294-1296.
2. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol. 1994;12:1323-1334.
3. Geller DA, Tsung A, Marsh JW, et al. Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center. J Gastrointest Surg. 2006;10:63-68.
4. Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500-507.
5. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma [editorial; comment]. N Engl J Med. 1999;340:798-799.
6. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353:1253-1257.
7. Society, A. C. Cancer Facts and Figures. 2006.
8. Lemire JM, Fausto N. Multiple alpha-fetoprotein RNAs in adult rat liver: cell type-specific expression and differential regulation. Cancer Res. 1991;51:4656-4664.
9. Ohguchi S, Nakatsukasa H, Higashi T, et al. Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy. Hepatology. 1998;27:599-607.
10. Abelev GI, Eraiser TL. Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin Cancer Biol. 1999;9:95-107.
11. Bayati N, Silverman AL, Gordon SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol. 1998;93:2452-2456.
12. Chen DS, Sung JL. Relationship of hepatitis B surface antigen to serum alpha-fetoprotein in nonmalignant diseases of the liver. Cancer. 1979;44:984-992.
13. Collazos J, Genolla J, Ruibal A. Preliminary study of alpha-fetoprotein in nonmalignant liver diseases. A clinico-biochemical evaluation. Int J Biol Markers. 1992;7:97-102.
14. Harada T, Shigeta K, Noda K, et al. Clinical implications of alpha-fetoprotein in liver cirrhosis: five-year follow-up study. Hepatogastroenterology. 1980;27:169-175.
15. Hu KQ, Kyulo NL, Lim N, et al. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol. 2004;99:860-865.
16. Lazarevich NL. Molecular mechanisms of alpha-fetoprotein gene expression. Biochemistry (Mosc). 2000;65:117-133.
17. Kubota M, Yagi M, Kanada S, et al. Effect of postoperative chemotherapy on the serum alpha-fetoprotein level in hepatoblastoma. J Pediatr Surg. 2004;39:1775-1778.
18. Nakagawara A, Ikeda K, Tsuneyoshi M, et al. Hepatoblastoma producing both alpha-fetoprotein and human chorionic gonadotropin. Clinicopathologic analysis of four cases and a review of the literature. Cancer. 1985;56:1636-1642.
19. Van Tornout JM, Buckley JD, Quinn JJ, et al. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children's Cancer Group. J Clin Oncol. 1997;15:1190-1197.
20. Newby D, Dalgliesh G, Lyall F, et al. Alphafetoprotein and alphafetoprotein receptor expression in the normal human placenta at term. Placenta. 2005;26:190-200.
21. Suzuki Y, Zeng CQ, Alpert E. Isolation and partial characterization of a specific alpha-fetoprotein receptor on human monocytes. J Clin Invest. 1992;90:1530-1536.
22. Torres CA, Iwasaki A, Barber BH, et al. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J Immunol. 1997;158:4529-4532.
23. Macho A, Aguilar JJ, Naval J, et al. Expression of alpha-fetoprotein and interleukin 2 receptors and impairment of membrane fluidity in peripheral blood mononuclear cells from AIDS and related syndromes. AIDS Res Hum Retroviruses. 1994;10:995-1001.
24. Severin SE, Rodina AV, Nitsvetov MB, et al. Regulation of antitumor activity using monoclonal antibodies to alpha-fetoprotein receptor and after immunization with this protein. Russ J Immunol. 2001;6:249-256.
25. Cavin LG, Venkatraman M, Factor VM, et al. Regulation of alpha-fetoprotein by nuclear factor-kappaB protects hepatocytes from tumor necrosis factor-alpha cytotoxicity during fetal liver development and hepatic oncogenesis. Cancer Res. 2004;64:7030-7038.
26. Cohen BL, Orn A, Gronvik KO, et al. Suppression by alphafetoprotein of murine natural killer cell activity stimulated in vitro and in vivo by interferon and interleukin 2. Scand J Immunol. 1986;23:211-223.
27. Dattwyler RJ, Tomasi TB. Inhibition of sensitization of T-cells by alpha-fetoprotein. Int J Cancer. 1975;16:942-945.
28. Geissler M, Mohr L, Ali MY, et al. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma. Z Gastroenterol. 2003;41:1101-1110.
29. Lu CY, Changelian PS, Unanue ER. Alpha-fetoprotein inhibits macrophage expression of Ia antigens. J Immunol. 1984;132:1722-1727.
30. Matsuura E, Kang Y, Kitakawa H, et al. Modulation of T cell function by alpha-fetoprotein: an in vivo study on porcine thyroid peroxidase-induced experimental autoimmune thyroiditis in transgenic mice producing human alpha-fetoprotein. Tumour Biol. 1999;20:162-171.
31. Neumann U. Inhibition of in vitro lymphocyte blastogenesis by chicken alpha-fetoprotein. Comp Immunol Microbiol Infect Dis. 1984;7:43-52.
32. Peck AB, Murgita RA, Wigzell H. Cellular and genetic restrictions in the immunoregulatory activity of alpha-fetoprotein. III. Role of the MLC-stimulating cell population in alpha-fetoprotein-induced suppression of T cell-mediated cytotoxicity. J Immunol. 1982;128:1134-1140.
33. Ritter M, Ali MY, Grimm CF, et al. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. J Hepatol. 2004;41:999-1007.
34. Semeniuk DJ, Boismenu R, Tam J, et al. Evidence that immunosuppression is an intrinsic property of the alpha-fetoprotein molecule. Adv Exp Med Biol. 1995;383:255-269.
35. Toder V, Blank M, Nebel L. Immunoregulatory mechanisms in pregnancy. 1. Evidence for the alpha-fetoprotein-induced generation of suppressor cells in vitro. Transplantation. 1982;33:41-44.
36. Um SH, Mulhall C, Alisa A, et al. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol. 2004;173:1772-1778.
37. Butterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology. 2004;127:S232-S241.
38. Butterfield LH, Koh A, Meng W, et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 1999;59:3134-3142.
39. Butterfield LH, Meng WS, Koh A, et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001;166:5300-5308.
40. Butterfield LH, Ribas A. Immunotherapy of hepatocellular carcinoma. Expert Opin Biol Ther. 2002;2:123-133.
41. Meng WS, Butterfield LH, Ribas A, et al. Alpha-fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 2001;61:8782-8786.
42. Meng WS, Butterfield LH, Ribas A, et al. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol. 2000;37:943-950.
43. Vollmer CM Jr, Eilber FC, Butterfield LH, et al. Alpha-fetoprotein- specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 1999;59:3064-3067.
44. Liu Y, Daley S, Evdokimova VN, et al. Hierarchy of AFP-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J Immunol. 2006;177:712-721.
45. Butterfield LH, Ribas A, Dissette VB, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006;12:2817-2825.
46. Butterfield LH, Ribas A, Meng WS, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003;9:5902-5908.
47. Alisa A, Ives A, Pathan AA, et al. Analysis of CD4+ T-cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res. 2005;11:6686-6694.
48. Hanke P, Rabe C, Serwe M, et al. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol. 2002;37:949-955.
49. Janssen EM, Droin NM, Lemmens EE, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005;434:88-93.
50. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852-856.
51. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003;300:339-342.
52. Butterfield LH, Jilani SM, Chakraborty NG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 1998;161:5607-5613.
53. Toloza EM, Hunt K, Miller AR, et al. Transduction of murine and human tumors using recombinant adenovirus vectors. Ann Surg Oncol. 1997;4:70-79.
54. Arthur JF, Butterfield LH, Roth MD, et al. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 1997;4:17-25.
55. Herr W, Linn B, Leister N, et al. The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods. 1997;203:141-152.
56. Gorelik E, Landsittel DP, Marrangoni AM, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:981-987.
57. Mehrotra S, Chhabra A, Chakraborty A, et al. Antigen presentation by MART-1 adenovirus-transduced interleukin-10-polarized human monocyte-derived dendritic cells. Immunology. 2004;113:472-481.
58. Guo J, Cai M, Wei D, et al. Immune responses of dendritic cells after loaded with cytotoxicity T lymphocyte epitope based peptide of human alpha-fetoprotein (hAFP). Zhonghua Gan Zang Bing Za Zhi. 2002;10:178-180.
59. Schumacher L, Ribas A, Dissette VB, et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother. 2004;27:191-200.
60. Hensley SE, Giles-Davis W, McCoy KC, et al. Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol. 2005;175:6032-6041.
61. Whitmire JK, Benning N, Whitton JL. Cutting edge: early IFN-gamma signaling directly enhances primary antiviral CD4+ T cell responses. J Immunol. 2005;175:5624-5628.
62. Malek TR. T helper cells, IL-2 and the generation of cytotoxic T-cell responses. Trends Immunol. 2002;23:465-467.
63. Malek TR, Yu A, Scibelli P, et al. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J Immunol. 2001;166:1675-1683.
64. Tham EL, Shrikant P, Mescher MF. Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response. J Immunol. 2002;168:1190-1197.
65. Bisgaard HC, Nagy P, Ton PT, et al. Modulation of keratin 14 and alpha-fetoprotein expression during hepatic oval cell proliferation and liver regeneration. J Cell Physiol. 1994;159:475-484.
66. Kim Y, Nakagawa Y, Sugiyama H, et al. Induction of CD4+ murine natural killer T-like cells by immunization with syngeneic thymoma expressing embryonic alpha-fetoprotein. Cell Immunol. 2003;226:1-10.
67. Mackiewicz A, Speroff T, Ganapathi MK, et al. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol. 1991;146:3032-3037.
68. Semenkova LN, Dudich EI, Dudich IV, et al. Alpha-fetoprotein as a TNF resistance factor for the human hepatocarcinoma cell line HepG2. Tumour Biol. 1997;18:30-40.
69. Yamashita T, Nakane A, Watanabe T, et al. Evidence that alpha-fetoprotein suppresses the immunological function in transgenic mice. Biochem Biophys Res Commun. 1994;201:1154-1159.
70. Gao J, Chen M, Ren H. Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2005;13:432-435.
71. Ribas A, Butterfield LH, Hu B, et al. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res. 2000;60:2218-2224.